{"entity":{"id":"psivac","kind":"company","name":"PsiVac","aka":["PsiVac Ltd"],"tldr":"PsiVac is a London company developing Ixovex-1, a genetically modified cold virus (adenovirus) designed to infect and burst cancer cells while largely sparing normal cells, and to rouse the immune system. It is in an early trial, alone and with the immunotherapy pembrolizumab.","summary":"PsiVac Ltd, at 55a Welbeck Street, London, develops oncolytic adenoviruses using what it describes as a patented multi-modality delivery system that makes a common oncolytic virus cancer-selective. Its founder, chairman and chief executive is Professor Ghassan Alusi, a head and neck surgeon at Barts Health. Its lead candidate Ixovex-1 is in a phase 1/2 study as a single agent and with pembrolizumab in solid tumours including head and neck cancer, run in the United Kingdom with IQVIA Biotech (NCT06549946). Its first registered cancer trial, NCT06549946, was posted on ClinicalTrials.gov in August 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.psivac.com/"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":["immunotherapy"],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06549946"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 29 October 2026: psivac.com home and contact pages. Founding year not stated on the company website (the footer carries a 2018 copyright line). Financing not stated.","Trial facts from the ClinicalTrials.gov record NCT06549946, read on 29 October 2026; no results were read."],"hq":"London","country":"GB","companyType":"biotech","website":"https://www.psivac.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/psivac/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}],"trial":[{"id":"nct06549946","kind":"trial","name":"Ixovex-1 Single Agent and Combination Therapy","route":"/trials/nct06549946/"}]}}